Endothelial dysfunction contributes to microvascular and macrovascular complications of diabetes. A major defense of endothelial cells against vascular injury is endothelial nitric oxide synthase (eNOS), which generates nitric oxide (NO) in the presence of optimal concentrations of the substrate L-arginine and the cofactor tetrahydrobiopterin (BH4). Diabetic nephropathy (DN) is associated with a state of progressive NO deficiency due to eNOS dysfunction, a phenomenon referred to as """"""""uncoupling"""""""". eNOS dysfunction and decreased bioavailability of NO in the kidney have recently been reported in an experimental model of type 1 diabetes and the protective role of NO generation by eNOS in the kidney has been conclusively established by recent studies showing that eNOS knockout mice made diabetic develop advanced lesions and progressive DN. While these studies established a protective role for eNOS, the mechanism(s) by which eNOS is inactivated in DN are not clearly identified. Understanding the mechanisms of uncoupling of eNOS in type 1 diabetes is essential if the above observations are to be translated to clinical therapeutic regimens aimed at recoupling of eNOS, restoring NO production and decreasing reactive oxygen species (ROS) generation during the course of DN. Our preliminary data show that in isolated glomeruli, where endothelium and mesangium are intact, eNOS generates ROS and lesser amount of NO upon stimulation with high glucose concentration (HG) or angiotensin II (Ang II). eNOS is expressed in glomerular endothelial as well as in mesangial cells and the enzyme generates ROS and less NO after exposure of the cells to HG or Ang II. HG and Ang II also cause a decrease in dihydrofolate reductase and an increase in arginase I protein levels, two enzymes that regulate availability of BH4 and L-arginine, respectively. Ang II and HG result in cell hypertrophy and fibronectin expression in cultured renal cells through generation of ROS via the NAD(P)H oxidase isoenzyme Nox4. Inhibition of Nox4 oxidase using an antisense oligonucleotide therapy reduces diabetes-induced Nox4 expression, renal ROS generation, hypertrophy and fibronectin expression in type 1 diabetic rats. Our central hypothesis is that the ROS generated by Nox oxidases and specifically Nox4 play a pivotal role in eNOS uncoupling in the glomerular mesangium and endothelium and in the kidney in diabetes, thereby resulting not only in the elimination of the protective effect of eNOS, but also converting the enzyme to a phlogistic mediator that further enhances ROS generation. We propose that ROS generated by Nox4 or other Nox oxidases result in oxidation of cysteine residues in the zincthiolate cluster essential for the activity of eNOS, and or decrease the levels of the substrate L-arginine and the cofactor BH4. The role of these pathways in hypertrophy, fibrogenic cytokine expression extracellular matrix accumulation and nuclear factor-kappaB activation will be explored in vitro and in vivo.

Public Health Relevance

Diabetes and diabetic nephropathy are major causes of morbidity in the general population. Oxidative stress and decrease in nitric oxide bioavailability contributes to diabetic complications;however, the precise sources of oxygen radicals and the processes involved in these events are not completely defined. It is our hope that identifying specific sources of oxidants will allow targeted therapy to prevent diabetic nephropathy and our long-term goal is to move our findings into the translational arena to treat the patients with specific antioxidant therapy.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DKUS-B (02))
Program Officer
Rys-Sikora, Krystyna E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center San Antonio
Internal Medicine/Medicine
Schools of Medicine
San Antonio
United States
Zip Code
Wagner, Brent; Drel, Viktor; Gorin, Yves (2016) Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 311:F1-F11
Drel, Viktor R; Tan, Chunyan; Barnes, Jeffrey L et al. (2016) Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis. FASEB J 30:3026-38
Thakur, Sachin; Viswanadhapalli, Suryavathi; Kopp, Jeffrey B et al. (2015) Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation. Am J Pathol 185:2168-80
Gorin, Yves; Wauquier, Fabien (2015) Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease. Mol Cells 38:285-96
Feliers, Denis; Lee, Duck-Yoon; Gorin, Yves et al. (2015) Symmetric dimethylarginine alters endothelial nitric oxide activity in glomerular endothelial cells. Cell Signal 27:1-5
Lee, Hak Joo; Feliers, Denis; Mariappan, Meenalakshmi M et al. (2015) Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in Podocytes. J Biol Chem 290:12014-26
Gorin, Yves; Cavaglieri, Rita C; Khazim, Khaled et al. (2015) Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 308:F1276-87
Wagner, Brent; Gorin, Yves (2014) Src tyrosine kinase mediates platelet-derived growth factor BB-induced and redox-dependent migration in metanephric mesenchymal cells. Am J Physiol Renal Physiol 306:F85-97
Bera, Amit; Das, Falguni; Ghosh-Choudhury, Nandini et al. (2014) A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF. Am J Physiol Cell Physiol 306:C1089-100
Gorin, Yves (2013) Nox4 as a potential therapeutic target for treatment of uremic toxicity associated to chronic kidney disease. Kidney Int 83:541-3

Showing the most recent 10 out of 23 publications